Biocon的股份上升到52周高点, 吸引其生物相似单位进行合并会谈, 目的是减少债务, 提高价值。 Biocon's stock rose to a 52-week high on merger talks for its biosimilars unit, aiming to cut debt and boost value.

Biocon公司股份上升超过4%, 达到52周高点, 该公司正在评估其生物类似单位Biocon Biologics与母公司合并的情况, 其价值可能达45亿美元。 Biocon's shares rose over 4% to a 52-week high amid reports it is evaluating a merger of its biosimilars unit, Biocon Biologics, with the parent company, potentially valued at $4.5 billion. 这一举措旨在减少2022年Viatris购买的12亿美元的收购债务,并释放股东价值。 The move aims to reduce $1.2 billion in acquisition debt from the 2022 Viatris purchase and unlock shareholder value. 该公司报告第二季度成果强劲,在新产品推出的驱动下,其净利润为84.5克朗,收入增长19.6%,生物类同年收入增长25%。 The company reported strong second-quarter results, with net profit of ₹84.5 crore, 19.6% revenue growth, and 25% year-on-year revenue increase in biosimilars, driven by new product launches. 中介公司保持了“Buy”评级,以盈利能力和减债为例,6个月内股票增加了28%。 Brokerages maintained 'Buy' ratings, citing improved profitability and debt reduction, with the stock up 28% in six months.